Linear association between serum potassium levels and 28-day mortality among ICU patients with diabetes and sepsis: a multicenter study

Abstract

Background:

Dysregulation of serum potassium is a common electrolyte disturbance in critically ill patients, and both hypokalemia and hyperkalemia have been linked to adverse outcomes in sepsis. However, the relationship between serum potassium levels and mortality in ICU patients with diabetes and sepsis remains poorly understood.

Methods:

A retrospective cohort study was conducted using data from the eICU Collaborative Research Database (2014–2015). The study included 5,104 adult ICU patients with diabetes and sepsis from 208 hospitals in the U.S. Serum potassium levels measured within 24 h of ICU admission were categorized into hypokalemia (<3.5 mmol/L), normokalemia (3.5–5.0 mmol/L), and hyperkalemia (>5.0 mmol/L). Multivariable logistic regression models were used to assess the association between serum potassium levels and 28-day ICU mortality.

Results:

Of the 5,104 patients (mean age, 66.8 years; 49.1% male), 1,046 (20.5%) had hypokalemia, 3,377 (66.2%) had normokalemia, and 681 (13.3%) had hyperkalemia. After adjusting for demographic factors, comorbidities, and treatment measures, each 1 mmol/L increase in serum potassium was associated with a 25% higher risk of 28-day mortality (adjusted OR, 1.25; 95% CI, 1.07–1.47). Compared to hypokalemia, hyperkalemia was associated with significantly higher mortality risk (adjusted OR, 1.86; 95% CI, 1.17–2.96). A linear relationship was observed between serum potassium levels and mortality (P = 0.006), differing from the previously reported U-shaped relationship in general ICU populations.

Conclusions and relevance:

Elevated serum potassium levels were independently associated with increased 28-day mortality in ICU patients with diabetes and sepsis. These findings suggest that potassium management strategies should be specifically tailored for this high-risk patient population.

Introduction

Sepsis remains a major global health challenge, affecting millions of patients annually and carrying substantial mortality rates, particularly among those requiring intensive care unit (ICU) admission. Despite advances in critical care medicine, the mortality rate for patients with sepsis in ICUs ranges from 25 to 50%, highlighting the urgent need to identify modifiable risk factors that could improve outcomes (1, 2).

Dysregulation of serum potassium, a crucial electrolyte for maintaining cellular function and cardiovascular stability, has been associated with increased mortality risk in critically ill patients (3, 4). Several studies have suggested a U-shaped relationship between serum potassium levels and mortality in general and septic ICU populations, with both hypokalemia and hyperkalemia linked to adverse outcomes (5–9). However, this relationship may not be consistent across all patient subgroups. Recent evidence suggests that the association between serum potassium and mortality might vary depending on underlying comorbidities and patient characteristics (10, 11).

Diabetes mellitus, affecting ~20–35% of ICU patients with sepsis, has been identified as a significant risk factor for potassium homeostasis disorders (12–14). Previous research demonstrated that diabetes is independently associated with an increased risk of hyperkalemia, potentially due to insulin resistance, impaired potassium cellular uptake, and diabetic kidney disease (15–18). However, the relationship between serum potassium levels and mortality specifically in diabetic patients with sepsis remains poorly understood, as most existing studies have either excluded this population or included it as part of general ICU cohorts (5–8, 19–21).

Therefore, we conducted this study to investigate the association between serum potassium levels and 28-day mortality in ICU patients with both sepsis and diabetes, aiming to better understand whether the traditional U-shaped relationship between potassium and mortality holds true in this specific population.

Methods

Data source and population

The study participants were identified from the eICU Collaborative Research Database (version 2.0) (22), a multicenter database comprising the data of patients admitted to the intensive care unit (ICU) in the United States (US). This database contains high-granularity medical data from 200,859 admissions to the ICUs across 208 hospitals during 2014–2015 and is accessible to the public. The eICU Collaborative Research Database includes diverse clinical data, such as information on demographic characteristics, vital signs, laboratory tests, disease severity measures, diagnosis, and treatment approaches. The data were collected and normalized based on an effective electronic clinical management system. One of our authors was responsible for data extraction after gaining access to the database.

In this study, all patients diagnosed with sepsis and diabetes were considered for inclusion. We excluded patients with missing values of serum potassium within 24 h of admission. Ultimately, 5,104 eligible participants were included in our final analysis (Figure 1). Serum potassium levels measured within 24 h of ICU admission were categorized into hypokalemia (<3.5 mmol/L), normokalemia (3.5–5.0 mmol/L), and hyperkalemia (>5.0 mmol/L), consistent with commonly used clinical thresholds.

Figure 1

Variable extraction

Baseline characteristics of patients, including demographic data, comorbidities, source of infection, clinical characteristics, laboratory values, and treatment strategies, within 24 h of ICU admission were extracted to avoid potential confounders. Demographics included age, sex and ethnicity. Comorbidities included acute kidney injury (AKI), acute myocardial infarction (AMI), congestive heart failure (CHF), cardiac arrhythmia, pneumonia, chronic obstructive pulmonary disease (COPD), cirrhosis, metastatic cancer, lymphoma, leukemia and immunosuppression. Source of infection included pulmonary, renal/urinary tract, gastrointestinal, cutaneous/soft tissue, gynecologic, other or unknown infection. Clinical characteristics included body mass index (BMI) and sequential organ failure assessment (SOFA) score. Laboratory parameters included serum potassium, serum creatinine, blood urea nitrogen (BUN), glucose, serum sodium, serum chloride, ionized calcium, serum albumin, serum prealbumin, 24 h urine protein, hemoglobin, platelet count, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), Troponin-I, lactate dehydrogenase (LDH), creatine phosphokinase-myocardial band (CPK-MB), creatine phosphokinase (CPK), low-density lipoprotein cholesterol (LDLc), total cholesterol, triglycerides, high-density lipoprotein cholesterol (HDLc), uric acid, lipase and amylase. Regarding treatment measures, the usage of mechanical ventilation, dialysis, and vasopressor were included.

Outcomes

Primary outcome were defined as all-cause 28-day mortality in ICU.

Statistical analysis

Depending on whether or not it conformed to a normal distribution, continuous variables were presented as mean (standard deviation). Categorical variables were described as frequencies (percentages). The differences among individuals were assessed using the Kruskal-Wallis rank-sum test or Fisher's exact test. A two-sided P-value <0.05 was considered statistically significant.

To investigate the functional form of the relationship between serum potassium levels and 28-day ICU mortality, we conducted a smooth curve fitting analysis using generalized additive models with smoothing splines. In this analysis, we adjusted for age, sex, ethnicity, comorbidities (AKI, CHF, metastatic cancer), BMI, SOFA score, laboratory values (serum creatinine, BUN, glucose, serum sodium, serum chloride, serum albumin, and platelet count) and treatment measures (use of mechanical ventilation and dialysis).

After examining the relationship pattern, we used logistic regression models to quantify the association between serum potassium and 28-day ICU mortality. Data were presented as odds ratios (OR) with 95% confidence intervals (CI) to represent the effect of serum potassium on 28-day ICU mortality risk. For multivariable models, we included factors previously demonstrated to be prognostically significant, variables considered clinically important, and covariates identified in univariate logistic regression as significant predictors of mortality. We constructed the following sequential models to determine the influence of potential confounders on the serum potassium-mortality relationship: unadjusted; model 1, adjusted only for age and sex; model 2, adjusted for age, sex, and serum creatinine; and model 3, fully adjusted for age, sex, ethnicity, comorbidities (AKI, CHF, metastatic cancer), BMI, SOFA score, laboratory values (serum creatinine, BUN, glucose, serum sodium, serum chloride, serum albumin, and platelet count), and treatment measures (mechanical ventilation and dialysis). The covariates in the fully adjusted model were consistent with those used in the previous smooth curve fitting analysis. In all models, 28-day ICU mortality was the dependent variable, while serum potassium was analyzed as a continuous variable, as categorical variables based on clinical thresholds (<3.5, 3.5–5.0, >5.0 mmol/L), and as ordinal categories to assess for potential dose-response relationships.

To explore potential effect modification, we established subgroup-stratified models examining the association between serum potassium and 28-day ICU mortality across different patient characteristics, including age, sex, comorbidities (AKI, CHF, metastatic cancer), clinical parameters (BMI, SOFA score), laboratory values (serum creatinine, BUN, glucose, serum sodium, serum chloride, serum albumin, platelets), and treatment measures (mechanical ventilation and dialysis).

The statistical analysis was conducted using EmpowerStats (V4.2, https://www.empowerstats.net/en/) and R (V3.4.3, http://www.R-project.org).

Results

Patient characteristics and clinical features

In this cohort of 5,104 ICU patients with diabetes and sepsis (mean age, 66.8 years; 49.1% male), patients were stratified into three groups based on serum potassium levels: hypokalemia (<3.5 mmol/L, n = 1,046), normokalemia (3.5–5.0 mmol/L, n = 3,377), and hyperkalemia (>5.0 mmol/L, n = 681). Significant differences were observed in age (65.0 ± 13.9 vs. 67.4 ± 13.1 vs. 66.5 ± 13.1 years, P < 0.001) and sex distribution (male: 57.4% vs. 47.2% vs. 45.5%, P < 0.001) among the groups. Regarding comorbidities, AKI (38.5% vs. 23.5% vs. 20.4%, P < 0.001) and CHF (11.7% vs. 8.4% vs. 8.0%, P = 0.011) were more prevalent in the hyperkalemia group, while metastatic cancer showed lower prevalence (3.2% vs. 2.7% vs. 4.3%, P = 0.031). The hyperkalemia group demonstrated higher BMI (34.2 ± 11.2 vs. 32.0 ± 9.8 vs. 30.7 ± 9.3, P < 0.001) and more severe organ dysfunction (SOFA score: 5.7 ± 2.9 vs. 4.3 ± 2.9 vs. 4.1 ± 2.8, P < 0.001). Laboratory findings revealed significantly impaired renal function in the hyperkalemia group, with elevated serum creatinine (3.6 ± 2.5 vs. 2.1 ± 1.9 vs. 1.7 ± 1.5 mg/dL, P < 0.001) and BUN (58.6 ± 30.9 vs. 37.6 ± 24.7 vs. 30.0 ± 21.1 mg/dL, P < 0.001). Additionally, the hyperkalemia group showed higher glucose levels (203.0 ± 138.9 vs. 185.4 ± 112.6 vs. 180.3 ± 112.6 mg/dL, P < 0.001) and lower serum sodium (136.3 ± 6.3 vs. 137.9 ± 5.7 vs. 139.5 ± 6.7 mmol/L, P < 0.001) and serum chloride levels (102.9 ± 7.7 vs. 104.3 ± 6.9 vs. 105.3 ± 8.0 mmol/L, P < 0.001). Higher platelet count (215.5 ± 119.8 vs. 206.7 ± 109.7 vs. 198.2 ± 107.2 × 10⁹/L, P = 0.008) were also observed in the hyperkalemia group. Regarding therapeutic interventions, the hyperkalemia group had higher rates of mechanical ventilation (35.1% vs. 24.8% vs. 28.5%, P < 0.001) and dialysis (15.0% vs. 10.2% vs. 6.9%, P < 0.001). Notably, the 28-day ICU mortality was significantly higher in the hyperkalemia group (14.4% vs. 7.1% vs. 6.2%, P < 0.001; Table 1).

To explore the relationship between serum potassium levels and 28-day mortality, we conducted a smooth curve fitting analysis using generalized additive models. After fully adjustment, the results demonstrated a linear relationship between serum potassium levels and 28-day mortality (effective degrees of freedom = 1.07; P = 0.006; Figure 2).

Figure 2

In the univariate analysis, serum potassium was significantly associated with increased mortality risk (OR 1.48, 95% CI 1.32–1.66, P < 0.001). This association between serum potassium levels and 28-day mortality remained consistent across most prespecified subgroups. Age-stratified analysis revealed that this association strengthened with increasing age. Gender stratification showed similar association strengths for both males and females. In comorbidity subgroup analyses, the association remained significant regardless of AKI or CHF. When stratified by organ dysfunction severity, the association was most pronounced in patients with moderate SOFA scores [3–4 points: OR, 1.51 (95% CI, 1.13–2.01)] and remained significant in those with severe organ dysfunction [SOFA ≥5: OR, 1.28 (95% CI, 1.13–1.45)]. Among patients with different degrees of kidney dysfunction, the strongest association was observed in those with moderate renal impairment [serum creatinine 1.2–2.4 mg/dL: OR, 1.39 (95% CI, 1.13–1.70)]. Moreover, this association was significant among patients not receiving dialysis [OR, 1.49 (95% CI, 1.32–1.68); P < 0.001], while this association was not statistically significant in patients undergoing dialysis [OR, 1.32 (95% CI, 0.95–1.82); P = 0.094]. The relationship remained significant across various levels of other clinical parameters, including BMI, glucose, serum albumin, and platelet counts and use of mechanical ventilation status (Table 2).

The association between serum potassium levels and 28-day mortality was evaluated using three different analytical approaches in multivariable models. Among 5,104 ICU patients with diabetes and sepsis, serum potassium levels were significantly associated with 28-day mortality. In the fully adjusted model (Model 3), each 1 mmol/L increase in serum potassium concentration was associated with a 25% higher risk of 28-day ICU mortality [OR, 1.25 (95% CI, 1.07–1.47), P = 0.006]. When analyzing serum potassium as a categorical variable, compared with patients with serum potassium <3.5 mmol/L, those with serum potassium >5.0 mmol/L showed significantly higher mortality risk in the unadjusted analysis [OR, 2.54 (95% CI, 1.82–3.53), P < 0.001]. This association remained stable after adjusting for age and sex [Model 1: OR, 2.49 (95% CI, 1.79–3.47), P < 0.001], slightly attenuated after additional adjustment for serum creatinine [Model 2: OR, 2.06 (95% CI, 1.46–2.92), P < 0.001], and remained significant although further attenuated in the fully adjusted model [Model 3: OR, 1.86 (95% CI, 1.17–2.96), P = 0.009]. Patients with normal potassium levels (3.5–5.0 mmol/L) showed no significant difference in mortality risk compared to those with hypokalemia across all models (Table 3). When treating serum potassium categories as ordinal variables, each category increase was associated with higher mortality risk, with the association remaining significant after full adjustment [OR, 1.38 (95% CI, 1.09–1.75); P = 0.008].

Discussion

In this large multicenter cohort study of 5,104 ICU patients with both diabetes and sepsis, we found a significant association between elevated serum potassium levels and increased 28-day mortality. Unlike the previously reported U-shaped relationship in general ICU populations (5–7), our study revealed a linear relationship between serum potassium levels and mortality risk in this specific patient population. After comprehensive adjustment for potential confounders, each 1 mmol/L increase in serum potassium was associated with a 25% higher risk of 28-day ICU mortality, and patients with hyperkalemia (>5.0 mmol/L) showed a 86% higher 28-day ICU mortality risk compared to those with hypokalemia (<3.5 mmol/L).

Our findings both confirm and extend previous research on the relationship between serum potassium and mortality in critically ill patients. While earlier studies have suggested a U-shaped relationship between potassium levels and mortality in general ICU populations (5–7), our results demonstrate a different pattern in diabetic patients with sepsis. This discrepancy might be explained by the unique pathophysiological characteristics of our study population. Notably, our findings align with previous research (11, 17, 23), which found that even mild hyperkalemia was associated with increased mortality in patients with diabetes, although these study were not specific to sepsis.

Several mechanisms might explain the observed association between hyperkalemia and increased mortality in our study population. First, diabetes and sepsis can synergistically impair potassium homeostasis through multiple pathways (24). Insulin resistance in diabetic patients can reduce cellular potassium uptake, while sepsis-induced AKI may impair potassium excretion (25, 26). Second, hyperkalemia may serve as a marker of more severe organ dysfunction (1), particularly given the higher SOFA scores observed in our hyperkalemic group. Third, the direct cardiotoxic effects of hyperkalemia may be amplified in diabetic patients, who often have underlying cardiovascular disease (4, 20, 21, 27).

Our findings have several important clinical implications. First, we suggest that the traditional U-shaped relationship between potassium and mortality may not apply to ICU patients with diabetes and sepsis, warranting a different approach to potassium management in this population. Notably, serum potassium levels exceeding 5.0 mmol/L-a commonly accepted clinical threshold-were associated with a significantly increased risk of mortality, underscoring the need for close monitoring and proactive management of hyperkalemia in ICU patients with both diabetes and sepsis. Second, the linear relationship between serum potassium levels and mortality suggests that even modest elevations in serum potassium should prompt careful clinical attention. Third, our subgroup analyses identify particularly vulnerable populations (elderly, or patients with severe organ dysfunction) who may benefit from more intensive potassium monitoring and management.

Our study has several strengths, including its large sample size, multicenter design, and comprehensive adjustment for confounders. The consistency of findings across multiple analytical approaches and subgroups supports the robustness of our results.

However, several limitations should be acknowledged. First, as an observational, retrospective study, we cannot establish causality between hyperkalemia and mortality. Second, an important limitation is the absence of time-varying analysis of potassium concentrations. Serum potassium is a dynamic parameter in the ICU setting, and our single-point measurement at admission may not capture the full exposure to dyskalemia-related risk. Repeated measurements and analysis of potassium trajectories (e.g., mean, peak, or variability) could add significant depth to understanding the association with mortality, as suggested by previous studies (7, 28, 29). This limitation was primarily due to data availability constraints in the eICU database. Third, we lacked information about pre-admission medications that might affect potassium homeostasis.

Conclusion

In this large multicenter cohort study, we found that elevated serum potassium levels were independently associated with increased 28-day mortality among ICU patients with diabetes and sepsis. Unlike the U-shaped relationship previously observed in general ICU populations, our findings revealed a linear association between potassium levels and mortality risk in this specific patient group. These results suggest that careful monitoring and avoiding hyperkalemia may be particularly important in ICU patients with diabetes and sepsis, and that traditional thresholds for serum potassium management may need to be reconsidered for this population. Future prospective studies are needed to validate these findings and evaluate whether targeted potassium management strategies can improve outcomes in this vulnerable patient group.

References

• 1.

  Singer M Deutschman CS Seymour CW Shankar-Hari M Annane D Bauer M et al . The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA. (2016) 315:801–10. 10.1001/jama.2016.0287

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 2.

  Vincent J Jones G David S Olariu E Cadwell KK . Frequency and mortality of septic shock in Europe and North America: a systematic review and meta-analysis. Crit Care. (2019) 23:196. 10.1186/s13054-019-2478-6

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 3.

  Tongyoo S Viarasilpa T Permpikul C . Serum potassium levels and outcomes in critically ill patients in the medical intensive care unit. J Int Med Res. (2018) 46:1254–62. 10.1177/0300060517744427

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 4.

  Bouadma L Mankikian S Darmon M Argaud L Vinclair C Siami S et al . Influence of dyskalemia at admission and early dyskalemia correction on survival and cardiac events of critically ill patients. Crit Care. (2019) 23:415. 10.1186/s13054-019-2679-z

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 5.

  McMahon GM Mendu ML Gibbons FK Christopher KB . Association between hyperkalemia at critical care initiation and mortality. Intensive Care Med. (2012) 38:1834–42. 10.1007/s00134-012-2636-7

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 6.

  Hessels L Hoekstra M Mijzen LJ Vogelzang M Dieperink W Lansink AO et al . The relationship between serum potassium, potassium variability and in-hospital mortality in critically ill patients and a before-after analysis on the impact of computer-assisted potassium control. Crit Care. (2015) 19:4. 10.1186/s13054-014-0720-9

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 7.

  Engelhardt LJ Balzer F Müller MC Grunow JJ Spies CD Christopher KB et al . Association between potassium concentrations, variability and supplementation, and in-hospital mortality in ICU patients: a retrospective analysis. Ann Intensive Care. (2019) 9:100. 10.1186/s13613-019-0573-0

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 8.

  Zhao G Gu Y Chen Y Xia X . Association of serum potassium levels with mortality in critically ill patients with sepsis during hospitalization. PLoS ONE. (2024) 19:e0314872. 10.1371/journal.pone.0314872

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 9.

  Tang J Zhao P Li Y Liu S Chen L Chen Y et al . The relationship between potassium levels and 28-day mortality in sepsis patients: secondary data analysis using the MIMIC-IV database. Heliyon. (2024) 10:e31753. 10.1016/j.heliyon.2024.e31753

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 10.

  Chen Y Chang AR DeMarco MA Inker LA Matsushita K Ballew SH et al . Serum potassium, mortality, and kidney outcomes in the atherosclerosis risk in communities study. Mayo Clin Proc. (2016) 91:1403–12. 10.1016/j.mayocp.2016.05.018

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 11.

  Collins AJ Pitt B Reaven N Funk S McGaughey K Wilson D et al . Association of serum potassium with all-cause mortality in patients with and without heart failure, chronic kidney disease, and/or diabetes. Am J Nephrol. (2017) 46:213–21. 10.1159/000479802

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 12.

  Lu Z Tao G Sun X Zhang Y Jiang M Liu Y et al . Association of blood glucose level and glycemic variability with mortality in sepsis patients during ICU hospitalization. Front Public Health. (2022) 10:857368. 10.3389/fpubh.2022.857368

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 13.

  van Vught LA Holman R de Jonge E de Keizer NF Van der Poll T . Diabetes is not associated with increased 90-day mortality risk in critically ill patients with sepsis. Crit Care Med. (2017) 45:e1026–35. 10.1097/CCM.0000000000002590

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 14.

  Alberti C Brun-Buisson C Burchardi H Martin C Goodman S Artigas A et al . Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study. Intensive Care Med. (2002) 28:108–21. 10.1007/s00134-001-1143-z

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 15.

  Jin H Lu R Zhang L Yao L Shao G Zuo L et al . Hyperkalemia burden and treatment patterns in Chinese patients on hemodialysis: final analysis of a prospective multicenter cohort study (PRECEDE-K). Ren Fail. (2024) 46:2384585. 10.1080/0886022X.2024.2384585

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 16.

  Hunter RW Bailey MA . Hyperkalemia: pathophysiology, risk factors and consequences. Nephrol Dial Transplant. (2019) 34(Suppl. 3):iii2–11. 10.1093/ndt/gfz206

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 17.

  Goia-Nishide K Coregliano-Ring L Rangel EB . Hyperkalemia in diabetes mellitus setting. Diseases. (2022) 10:20020. 10.3390/diseases10020020

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 18.

  Larivee NL Michaud JB More KM Wilson JA Tennankore KK . Hyperkalemia: prevalence, predictors and emerging treatments. Cardiol Ther. (2023) 12:35–63. 10.1007/s40119-022-00289-z

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 19.

  Hayes J Kalantar-Zadeh K Lu JL Turban S Anderson JE Kovesdy CP . Association of hypo- and hyperkalemia with disease progression and mortality in males with chronic kidney disease: the role of race. Nephron Clin Pract. (2012) 120:c8–16. 10.1159/000329511

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 20.

  Aldahl M Jensen AS Davidsen L Eriksen MA Møller Hansen S Nielsen BJ et al . Associations of serum potassium levels with mortality in chronic heart failure patients. Eur Heart J. (2017) 38:2890–6. 10.1093/eurheartj/ehx460

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 21.

  Goyal A Spertus JA Gosch K Venkitachalam L Jones PG Van den Berghe G et al . Serum potassium levels and mortality in acute myocardial infarction. JAMA. (2012) 307:157–64. 10.1001/jama.2011.1967

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 22.

  Pollard TJ Johnson AE Raffa JD Celi LA Mark RG Badawi O . The eICU Collaborative Research Database, a freely available multi-center database for critical care research. Sci Data. (2018) 5:180178. 10.1038/sdata.2018.178

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 23.

  Luo J Brunelli SM Jensen DE Yang A . Association between serum potassium and outcomes in patients with reduced kidney function. Clin J Am Soc Nephrol. (2016) 11:90–100. 10.2215/CJN.01730215

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 24.

  Udensi UK Tchounwou PB . Potassium homeostasis, oxidative stress, and human disease. Int J Clin Exp Physiol. (2017) 4:111–22. 10.4103/ijcep.ijcep_43_17

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 25.

  Palmer BF Clegg DJ . Physiology and pathophysiology of potassium homeostasis: core curriculum 2019. Am J Kidney Dis. (2019) 74:682–95. 10.1053/j.ajkd.2019.03.427

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 26.

  Bellomo R Kellum JA Ronco C Wald R Martensson J Maiden M et al . Acute kidney injury in sepsis. Intensive Care Med. (2017) 43:816–28. 10.1007/s00134-017-4755-7

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 27.

  Depret F Peacock WF Liu KD Rafique Z Rossignol P Legrand M . Management of hyperkalemia in the acutely ill patient. Ann Intensive Care. (2019) 9:32. 10.1186/s13613-019-0509-8

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 28.

  Zhang X Wang M Zhu Z Qu H Gu J Ni T et al . Serum potassium level, variability and in-hospital mortality in acute myocardial infarction. Eur J Clin Invest. (2022) 52:e13772. 10.1111/eci.13772

  • Pubmed Abstract
  • CrossRef
  • Google Scholar

• 29.

  Zhang Y Liang S Wen H . The impact of serum potassium ion variability on 28-day mortality in ICU patients. PLoS One, (2024). 19: p. e0310046. 10.1371/journal.pone.0310046

  • Pubmed Abstract
  • CrossRef
  • Google Scholar